BioDelivery Sciences International, Inc. (BDSI): Price and Financial Metrics


BioDelivery Sciences International, Inc. (BDSI): $5.59

-0.01 (-0.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BDSI to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BDSI POWR Grades


  • Quality is the dimension where BDSI ranks best; there it ranks ahead of 96.56% of US stocks.
  • The strongest trend for BDSI is in Growth, which has been heading down over the past 177 days.
  • BDSI ranks lowest in Momentum; there it ranks in the 7th percentile.

BDSI Stock Summary

  • With a price/earnings ratio of 6.79, Biodelivery Sciences International Inc P/E ratio is greater than that of about only 12.71% of stocks in our set with positive earnings.
  • Of note is the ratio of Biodelivery Sciences International Inc's sales and general administrative expense to its total operating expenses; 85.73% of US stocks have a lower such ratio.
  • With a year-over-year growth in debt of -25.06%, Biodelivery Sciences International Inc's debt growth rate surpasses merely 16.88% of about US stocks.
  • Stocks that are quantitatively similar to BDSI, based on their financial statements, market capitalization, and price volatility, are MHH, TRNS, KMT, ODC, and MLI.
  • Visit BDSI's SEC page to see the company's official filings. To visit the company's web site, go to www.bdsi.com.

BDSI Valuation Summary

  • BDSI's price/earnings ratio is 11.2; this is 69.32% lower than that of the median Healthcare stock.
  • Over the past 233 months, BDSI's price/earnings ratio has gone up 13.8.
  • Over the past 233 months, BDSI's price/sales ratio has gone down 18.6.

Below are key valuation metrics over time for BDSI.

Stock Date P/S P/B P/E EV/EBIT
BDSI 2021-08-31 2.3 3.3 11.2 7.9
BDSI 2021-08-30 2.3 3.3 11.0 7.7
BDSI 2021-08-27 2.3 3.3 11.1 7.8
BDSI 2021-08-26 2.3 3.3 11.2 7.9
BDSI 2021-08-25 2.2 3.2 10.9 7.6
BDSI 2021-08-24 2.3 3.3 10.9 7.7

BDSI Growth Metrics

    The 5 year net cashflow from operations growth rate now stands at 232.26%.
  • The 3 year net income to common stockholders growth rate now stands at 18.09%.
  • Its year over year price growth rate is now at -34.27%.
Over the past 34 months, BDSI's revenue has gone up $102,574,000.

The table below shows BDSI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 166.703 41.037 84.86
2021-09-30 165.718 38.305 31.166
2021-06-30 164.069 40.319 33.88
2021-03-31 159.212 29.691 25.981
2020-12-31 156.471 24.981 25.711
2020-09-30 145.94 30.886 14.818

BDSI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BDSI has a Quality Grade of A, ranking ahead of 98.15% of graded US stocks.
  • BDSI's asset turnover comes in at 0.683 -- ranking 43rd of 681 Pharmaceutical Products stocks.
  • INSM, CYRX, and CTLT are the stocks whose asset turnover ratios are most correlated with BDSI.

The table below shows BDSI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.683 0.855 0.451
2021-03-31 0.685 0.843 0.363
2020-12-31 0.708 0.842 0.381
2020-09-30 0.705 0.838 0.274
2020-06-30 0.708 0.827 0.160
2020-03-31 0.722 0.822 0.178

BDSI Price Target

For more insight on analysts targets of BDSI, see our BDSI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.88 Average Broker Recommendation 1.44 (Moderate Buy)

BDSI Stock Price Chart Interactive Chart >

Price chart for BDSI

BDSI Price/Volume Stats

Current price $5.59 52-week high $5.62
Prev. close $5.59 52-week low $2.50
Day low $5.59 Volume 2,107,400
Day high $5.60 Avg. volume 3,340,554
50-day MA $4.56 Dividend yield N/A
200-day MA $3.81 Market Cap 577.05M

BioDelivery Sciences International, Inc. (BDSI) Company Bio


BioDelivery Sciences International, Inc. engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company was founded in 1997 and is based in Raleigh, North Carolina.


BDSI Latest News Stream


Event/Time News Detail
Loading, please wait...

BDSI Latest Social Stream


Loading social stream, please wait...

View Full BDSI Social Stream

Latest BDSI News From Around the Web

Below are the latest news stories about Biodelivery Sciences International Inc that investors may wish to consider to help them evaluate BDSI as an investment opportunity.

BioDelivery Sciences launches migraine therapy in U.S.

BioDelivery Sciences International (BDSI), a specialty pharmaceutical company focused on chronic conditions, announced the U.S. launch of its oral migraine therapy Elyxyb. Also known as celecoxib oral solution, Elyxyb is the first and only oral solution approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute...

Seeking Alpha | February 24, 2022

BioDelivery Sciences International (BDSI) Just Flashed Golden Cross Signal: Do You Buy?

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

Yahoo | February 24, 2022

BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine

The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Expands BDSI Portfolio and Establishes Growth Platform in Neurology RALEIGH, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced the U.S. commercial launch and availability of ELYXYBTM (celecoxib

Yahoo | February 24, 2022

What to Expect From Precision BioSciences (DTIL) Q4 Earnings

On Precision BioSciences' (DTIL) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline.

Yahoo | February 22, 2022

Biotech Stock Roundup: BDSI Surges on Merger Deal, SGEN Down on Outlook & More

Merger updates from BioDelivery (BDSI) and Seagen (SGEN) earnings results are among a few key highlights from the biotech sector during the past week.

Yahoo | February 16, 2022

Read More 'BDSI' Stories Here

BDSI Price Returns

1-mo N/A
3-mo N/A
6-mo 81.49%
1-year N/A
3-year 21.00%
5-year 99.64%
YTD 80.32%
2021 -26.19%
2020 -33.54%
2019 70.81%
2018 25.42%
2017 68.57%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6404 seconds.